Wyeth Gets AIDS Vaccine Contract From NIAID

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

BETHESDA, Maryland-Wyeth Vaccines, a unit of Wyeth Pharmaceuticals, has won a 5-year, $22.8 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). The contract was awarded by NIAID’s HIV Vaccine Design and Development Teams (HVDDT) program, a public-private effort that seeks to accelerate the development of HIV vaccines.

BETHESDA, Maryland—Wyeth Vaccines, a unit of Wyeth Pharmaceuticals, has won a 5-year, $22.8 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). The contract was awarded by NIAID’s HIV Vaccine Design and Development Teams (HVDDT) program, a public-private effort that seeks to accelerate the development of HIV vaccines.

The vaccine under development by Wyeth has been shown to prevent an AIDS-like disease in monkeys, who became infected but did not become ill. It uses a genetically modified form of the vesicular stomatitis virus (VSV), which infects livestock, to ferry two HIV genes into the body, where the genes’ proteins boost the immune system against HIV.

Since the engineered virus contains only two HIV genes, not the entire virus, it cannot cause HIV infection. Furthermore, the hybrid virus is deliberately weakened to make it even safer.

Researchers hope the vaccine will stimulate both parts of the immune system: specialized immune cells to kill any HIV-infected cells and antibodies to neutralize free-floating HIV. The vaccine candidate had its origin in the Yale University laboratory of NIAID grantee John K. Rose, PhD. The study in monkeys showed it could be administered nasally, a potentially important advantage for any vaccine destined for widespread use. Expanded animal tests are underway.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.